Cite
HARVARD Citation
Kloppenburg, M. et al. (2019). Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the rheumatic diseases. 78 (3), pp. 413-420. [Online].